• PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri)
  • PRINT/CD-ROM: Despatched within 2 to 4 working days.

Global Vaccine Market Forecast to 2012

  • Publication Date:October 2010
  • Publisher:RNCOS
  • Product Type: Report
  • Pages:150

Global Vaccine Market Forecast to 2012

The prevalence of infectious and non-infectious diseases has significantly risen worldwide, leading to a spur in healthcare expenditure of both the developed and developing countries. Vaccine represents one of the most attractive and fast growing sectors, with players' revenue exceeding their expectations. Apart from the high disease prevalence, growing population and emergence of new pandemics are important growth drivers of the global vaccine market.

According to our new research report "Global Vaccine Market Forecast to 2012", the market for adult vaccines has been growing at faster rate than pediatric vaccines. The rising prevalence of life threatening diseases such as cancer and HIV is the prominent factor driving growth in the adult vaccine segment. A number of healthcare companies are focusing on cancer vaccine development process so that they can enhance their profit. The cancer vaccine market is expected to grow at a CAGR of 25% during 2009-2012 on the back of government support and rising participation of private players.

Our analysis of the global vaccine market with emphasis on the country level illustrates that the fast developing countries such as India and China will raise their overall share. Currently, these countries have been actively participating in market activities and vaccine manufacturers are booking profits on their sales. Besides, other countries will facilitate the development of vaccine market in their respective places in order to minimize health problems.

The report is an outcome of extensive research and objective analysis of the vaccine market in key countries of the world. It identifies all the necessary factors and aspects related to market and represent current industry status with future forecast on vaccine types and countries for 2009-2012. In addition, the description of key players and their recent activities have been provided to showcase an effective and balanced outlook of the global vaccine market.

  • 1. Analyst View
  • 2. Research Methodology
  • 3. Market Overview
  • 4. Key Market Drivers
    • 4.1 Improved Routine Immunization
    • 4.2 New Vaccine Introduction
    • 4.3 High Investments
    • 4.4 Support from Government and NGOs
  • 5. Emerging Trends
    • 5.1 Cancer Vaccines: Gaining Popularity
    • 5.2 Collaborations in Vaccine Industry
    • 5.3 Grants: Raising Support
  • 6. Industry Performance and Future Trends
  • 7. Major Vaccine Segments
    • 7.1 Basic Pediatrics
    • 7.2 Enhanced Pediatrics
    • 7.3 Proprietary Pediatrics
    • 7.4 Adult Vaccines
  • 8. Pediatric Vaccines
    • 8.1 Pneumococcal
    • 8.2 Polio
    • 8.3 Varicella
    • 8.4 Meningococcal
    • 8.5 Rotavirus
    • 8.6 DTP
    • 8.7 Measles, Mumps & Rubella (MMR)
    • 8.8 Tuberculosis
  • 9. Adult/Travel & Therapeutic Vaccines
    • 9.1 Hepatitis B
    • 9.2 Malaria
    • 9.3 Yellow Fever
    • 9.4 Rabies
    • 9.5 Japanese Encephalitis
    • 9.6 Typhoid
    • 9.7 West Nile
    • 9.8 HIV
    • 9.9 Cancer
    • 9.10 Influenza
  • 10. Key Geographical Markets
    • 10.1 US
    • 10.1.1 Market Overview
    • 10.1.2 Key Players
    • 10.1.3 Product Portfolio
    • 10.2 Europe
    • 10.2.1 Market Overview
    • 10.2.2 Key Players
    • 10.2.3 Product Portfolio
    • 10.3 China
    • 10.3.1 Market Overview
    • 10.3.2 Key Players
    • 10.3.3 Product Portfolio
    • 10.4 India
    • 10.4.1 Market Overview
    • 10.4.2 Key Players
    • 10.4.3 Product Portfolio
    • 10.5 Japan
    • 10.5.1 Market Overview
    • 10.5.2 Key Players
    • 10.5.3 Product Portfolio
    • 10.6 Brazil
    • 10.6.1 Market Overview
    • 10.6.2 Key Players
    • 10.6.3 Product Portfolio
  • 11. Investment Risk in Vaccine Industry
    • 11.1 High R&D Cost
    • 11.2 Lack of Infrastructure for Trials and Manufacturing
    • 11.3 Vaccine Supply
    • 11.4 Ineffective Distribution
  • 12. Key Mergers & Acquisitions
  • 13. Key Vaccine Brands Forecast to 2012
  • 14. Competitive Landscape
    • 14.1 Vaccine Majors
    • 14.1.1 Sanofi-Aventis
    • 14.1.2 Novartis
    • 14.2 Biotech-focused Vaccine Companies
    • 14.2.1 GSK
    • 14.2.2 Pfizer
    • 14.3 Domestic-focused Vaccine Companies
    • 14.3.1 Merck & Co.
  • List of Figures:
    • Figure 4-1: Global - Vaccine Market by Source of Funding (%), 2005 to 2010
    • Figure 6-1: Global - Vaccine Market (Billion US$), 2009-2012
    • Figure 7-1: Global - Basic Pediatric Vaccine Market (Million US$), 2007-2012
    • Figure 7-2: Global - Enhanced Pediatric Vaccine Market (Billion US$), 2007-2012
    • Figure 7-3: Global - Proprietary Pediatric Vaccine Market (Billion US$), 2007-2012
    • Figure 7-4: Global - Share of Adult Vaccine Sales in Vaccine Market (2008 & 2009)
    • Figure 7-5: Global - Adult Vaccine Market (Billion US$), 2009-2012
    • Figure 8-1: Global - Pneumococcal Vaccine Market (Billion US$), 2009-2012
    • Figure 8-2: Global - Number of Polio Incidences (2007-2009)
    • Figure 8-3: Global - Polio Vaccine Market (Million US$), 2004 & 2011
    • Figure 8-4: Global - Varicella Vaccine Market (Million US$), 2007 & 2008
    • Figure 8-5: Global - Meningococcal Vaccine (Million US$), 2009 & 2013
    • Figure 8-6: Global - Rotavirus Vaccine Market (Million US$), 2009 & 2010
    • Figure 8-7: Global - Rotavirus Vaccine Market by Region (%), 2010
    • Figure 8-8: Global - Number of Diphtheria Incidences by Region (2008)
    • Figure 8-9: Global - Number of Pertussis Incidences by Region (2008)
    • Figure 8-10: Global - Number of nTetanus Incidences by Region (2008)
    • Figure 8-11: Global - Number of tTetanus Incidences by Region (2008)
    • Figure 8-12: Global - Number of Measles Incidences by Region (2008)
    • Figure 8-13: Global - Number of Mumps Incidences by Region (2008)
    • Figure 8-14: Global - Number of Rubella Incidences by Region (2008)
    • Figure 8-15: Global - Number of Tuberculosis Incidences by Region ('000), 2008
    • Figure 9-1: Global - Hepatitis B Surface Antigen Prevalence (%), 2006
    • Figure 9-2: Global - Hepatitis B Vaccine Market (Billion US$), 2009-2012
    • Figure 9-3: Global - Yellow Fever Vaccine Market (Million US$), 2010 & 2013
    • Figure 9-4: Global - Japanese Encephalitis Market (Million US$), 2009-2012
    • Figure 9-5: Global - R&D Investment in AIDS Vaccine Development (Million US$), 2006-2009
    • Figure 9-6: Global - Sources for Funding in HIV Vaccine R&D (%), 2009
    • Figure 9-7: Global - Cancer Vaccine Market (Billion US$), 2009-2012
    • Figure 9-8: Global - Number of Cancer Vaccines in Various Phases of Clinical Developments by Type (Aug 2005)
    • Figure 9-9: Global - Seasonal Influenza Vaccine Market (Billion US$), 2009-2012
    • Figure 10-1: Global - Vaccine Market by Region (%), 2009
    • Figure 10-2: Global - Forecast for Vaccine Market by Region (%), 2012
    • Figure 10-3: US - Vaccine Market (Billion US$), 2008-2012
    • Figure 10-4: US - Pediatric Vaccine Market (Billion US$), 2010-2012
    • Figure 10-5: US - Hepatitis Vaccine Market (Billion US$), 2009-2012
    • Figure 10-6: US - Influenza Vaccine Production by Player (%), 2009
    • Figure 10-7: US - Influenza Vaccine Production and Consumption (Million Doses), 2004-2005 to 2008-2009
    • Figure 10-8: US - Influenza Vaccine Sales by Provider (%), 2007-2008
    • Figure 10-9: US - Influenza Vaccine Market (Million US$), 2009-2012
    • Figure 10-10: US - Travel Vaccine Market (Million US$), 2009-2012
    • Figure 10-11: US - Developmental Vaccine Market (Million US$), 2009-2012
    • Figure 10-12: Europe - Vaccine Market (Billion US$), 2009-2012
    • Figure 10-13: Europe - Share of Key Players in Vaccine Market (2008)
    • Figure 10-14: China - Vaccine Market (Billion US$), 2008-2012
    • Figure 10-15: China - Share of Key Players in Vaccine Market (2008)
    • Figure 10-16: China - Influenza Vaccine Market (Million US$), 2008-2012
    • Figure 10-17: India - Share of Domestic Consumption and Exports in Vaccine Market (2009)
    • Figure 10-18: India - Share of Private Sector in Domestic Vaccine Market (2008)
    • Figure 10-19: India - Vaccine Market (Million US$), 2008-09 to 2011-12
    • Figure 10-20: India - Share of Key Players in Vaccine Market (2006-07)
    • Figure 10-21: Japan - Vaccine Market (Billion US$), 2008-2012
    • Figure 10-22: Japan - Influenza Vaccine Production (Million Doses), 2007-08 & 2008-09
    • Figure 10-23: Japan - Share of Domestic and Foreign Players in Vaccine Market (2009)
    • Figure 10-24: Japan - Vaccine Market by Segment (%), 2009
    • Figure 10-25: Brazil - Vaccine Market (Billion BRL), 2009-2012
    • Figure 10-26: Brazil - Share of Public and Private Sector in Vaccine Market (2004)
    • Figure 10-27: Brazil - Share of Key Players in Private Sector Vaccine Market (2008)
    • Figure 11-1: Global - Dose Consumption and Revenue by Regional Income (%), 2005
    • Figure 14-1: Global - Vaccine Market by Player (%), 2009
  • List of Tables:
    • Table 8-1: Global - Pneumococcal Vaccine Supply
    • Table 8-2: Global - Leading DTP Vaccine Brands (Million US$), 2008
    • Table 8-3: Global - Leading MMR Vaccine Brands (Million US$), 2008
    • Table 9-1: Global - Number of HIV/AIDS Patients by Region (2008)
    • Table 9-2: US - Number of New Cancer Cases and Deaths (2009)
    • Table 9-3: Global - Five Year Relative Survival Rates by Stage of Cancer Diagnosis (%)
    • Table 9-4: Global - List of Launched and Under-development Cancer Vaccines by Indication
    • Table 9-5: Global - Top 5 Companies' Pandemic Influenza (H1N1) Vaccine Sales (Million US$), 2009
    • Table 10-1: China - Number of Reported Cases of Diseases Preventable by Vaccine (2008 & 2009)
    • Table 10-2: China - Vaccine Classification
    • Table 10-3: China - Annual Pediatric Vaccine Doses Requirement (Million)
    • Table 10-4: China - Revenues of Some Vaccine Manufacturing Biological Companies (Million RMB), 2006
    • Table 10-5: India - Sales of Top Five Vaccine Companies (Million US$), 2008-09
    • Table 10-6: Japan - Sales of Top Domestic Vaccine Manufacturers (Million JPY)
    • Table 10-7: Japan - Sales of Top Foreign Vaccine Players (Million JPY)
    • Table 10-8: Brazil - Public and Private Sector Vaccine Market (Million BRL)
    • Table 11-1: Health Statistics in Developed and Developing Countries (%)
    • Table 12-1: Global - Key Mergers & Acquisitions in Vaccine Market (2005 to 2009)
    • Table 13-1: Global - Top Launched Vaccine Brand Sales (Billion US$), 2009 & 2012
    • Table 13-2: Global - Forecast for Top Vaccine Brand Sales Under-development (Million US$), 2012
    • Table 14-1: Sanofi Aventis - Strengths and Weaknesses
    • Table 14-2: Novartis - Strengths and Weaknesses
    • Table 14-3: GSK - Strengths and Weaknesses
    • Table 14-4: Pfizer - Strengths and Weaknesses
    • Table 14-5: Global - Major Vaccine Companies (Segmentation by Revenue)
+44 20 8816 8548

Ask a question about Global Vaccine Market Forecast to 2012

Enter the characters you see in the picture below
Captcha